Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers

@article{Allison2012ClinicalSR,
  title={Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers},
  author={Malorye Allison},
  journal={Nature Biotechnology},
  year={2012},
  volume={30},
  pages={906-907}
}
volume 30 number 10 oCTober 2012 nature biotechnology The news that Thousand Oaks, California– based Amgen halted the phase 3 trials of ganitumab (AMG-479) in metastatic pancreatic cancer appears to have pounded a nail in approaches attempting to target the insulin-like growth factor 1 receptor (IGF-1R) in cancer. No safety concerns popped up, but the interim data provided no evidence the fully human monoclonal antibody (mAb) would benefit patients, echoing other studies with IGF-1R inhibitors… CONTINUE READING